This web publication constitutes a notice for the purposes of regulation 42ZCZS and regulation of the 42ZCX Therapeutic Goods Regulations 1990 (the Regulations). In accordance with regulations 42ZCZS and 42ZCZX, this notice publishes:
- the final decisions made by a delegate of the Secretary of the Department of Health, Disability and Ageing (the Delegate) pursuant to regulations 42ZCZR and 42ZCZU of the Regulations
- the reasons for the final decisions, and
- the dates of effect of these decisions.
This web publication also includes decisions made by the Delegate pursuant to subsection 52D(2) of Therapeutic Goods Act 1989 (the Act).
Final decisions and reasons
Contents
- Notice of final decisions to amend (or not amend) the current Poisons Standard
- Final decision on a proposed amendment referred to the Advisory Committee on Chemicals Scheduling (ACCS #38, March 2024)
- Ethyl lactyl retinoate
- Final decision on a proposed amendment referred to the Advisory Committees on Medicines and Chemicals Scheduling in joint session (ACMS-ACCS #37, November 2024)
- Intravenous potassium salts
- Final decision on a proposed amendment to the current Poisons Standard under regulation 42ZCZU
- Fenmezoditiaz
- Amendments to the Poison Standard in relation to New Chemical Entities (NCEs)
- Belantamab mafodotin
- Imlunestrant
- Loncastuximab tesirine
- Mirvetuximab soravtansine
- Sodium thiosulfate anhydrous
- Tofersen